John V. Oyler, Founder, Chairman and CEO at BeOne Medicines, shared a post by BeOne Medicines on LinkedIn, adding:
“Today marks an important milestone in our journey to transform cancer care and deliver better outcomes for patients around the world. Milestones like this are built on perseverance – on long hours, tough decisions, and the belief that what we are doing truly matters.”
Quoting BeOne Medicines‘s post:
“News for Investors and Media: BeOne announces positive topline results from a Phase 3 study evaluating our foundational BTK inhibitor in combination with rituximab versus standard chemoimmunotherapy in previously untreated adult mantle cell lymphoma (MCL) patients.
This is the first study of its kind to demonstrate superiority of a BTK inhibitor-based, chemotherapy-free regimen in this patient population.
Other articles about Lymphoma on OncoDaily.